EUROFINS SCIENT Long Term Debt 2018-2023 | ERFSF
EUROFINS SCIENT long term debt from 2018 to 2023. Long term debt can be defined as the sum of all long term debt fields.
- EUROFINS SCIENT long term debt for the quarter ending June 30, 2023 was $3.279B, a 1.55% increase year-over-year.
- EUROFINS SCIENT long term debt for 2022 was $3.279B, a 10.83% increase from 2021.
- EUROFINS SCIENT long term debt for 2021 was $2.958B, a 11.23% decline from 2020.
- EUROFINS SCIENT long term debt for 2020 was $3.332B, a 3.62% decline from 2019.
| EUROFINS SCIENT Annual Long Term Debt (Millions of US $) |
|
|---|---|
| 2022 | $3,279 |
| 2021 | $2,958 |
| 2020 | $3,332 |
| 2019 | $3,457 |
| 2018 | $3,267 |
| 2017 | $1,879 |
| 2016 | $ |
| 2015 | $ |
| EUROFINS SCIENT Quarterly Long Term Debt (Millions of US $) |
|
|---|---|
| 2022-12-31 | $3,279 |
| 2021-12-31 | $2,958 |
| 2021-06-30 | $3,045 |
| 2020-12-31 | $3,332 |
| 2020-06-30 | $3,228 |
| 2019-12-31 | $3,457 |
| 2019-06-30 | $2,995 |
| 2018-12-31 | $3,267 |
| 2018-06-30 | $1,993 |
| 2017-12-31 | $1,879 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $11.385B | $7.051B |
| Eurofins Scientific SE provides testing services. The company provides food and feed testing, bioanalytical, biopharma, pharma discovery, pharma early development, pharma central laboratory, biopharma product testing, genomic, agroscience, consumer product testing, forensic, environment testing and REACH services. It operates primarily in Benelux, France, Germany, North America, Nordic countries, the United Kingdom, Ireland and internationally. Eurofins Scientific SE is headquartered in Luxembourg. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $121.982B | 15.31 |
| Cencora (COR) | United States | $45.721B | 17.82 |
| ICON (ICLR) | Ireland | $24.881B | 23.49 |
| DiDi Global (DIDIY) | China | $23.865B | 0.00 |
| Avantor (AVTR) | United States | $16.588B | 24.42 |
| Viatris (VTRS) | United States | $13.847B | 3.98 |
| CochLear (CHEOY) | Australia | $13.505B | 0.00 |
| Revvity (RVTY) | United States | $12.674B | 22.21 |
| Medpace Holdings (MEDP) | United States | $12.327B | 40.56 |
| Charles River Laboratories (CRL) | United States | $11.986B | 21.85 |
| Natera (NTRA) | United States | $11.509B | 0.00 |
| Solventum (SOLV) | United States | $11.239B | 0.00 |
| Sonic Healthcare (SKHHY) | Australia | $8.205B | 0.00 |
| HealthEquity (HQY) | United States | $6.843B | 51.12 |
| Organon (OGN) | United States | $4.843B | 4.66 |
| Bausch + Lomb (BLCO) | Canada | $4.828B | 19.35 |
| Doximity (DOCS) | United States | $4.479B | 33.35 |
| PACS (PACS) | United States | $3.736B | 0.00 |
| Sotera Health (SHC) | United States | $3.190B | 15.65 |
| Surgery Partners (SGRY) | United States | $3.131B | 28.98 |
| Progyny (PGNY) | United States | $3.103B | 52.08 |
| GoodRx Holdings (GDRX) | United States | $2.753B | 139.40 |
| Life Times (LTH) | United States | $2.557B | 27.08 |
| Premier (PINC) | United States | $2.523B | 9.24 |
| AMN Healthcare Services Inc (AMN) | United States | $2.270B | 7.34 |
| Teladoc Health (TDOC) | United States | $2.172B | 0.00 |
| Agilon Health (AGL) | United States | $2.039B | 0.00 |
| BrightSpring Health Services (BTSG) | United States | $1.825B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.390B | 0.00 | |
| Agiliti (AGTI) | United States | $1.374B | 22.44 |
| NovoCure (NVCR) | Jersey | $1.371B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $0.995B | 0.00 |
| Pediatrix Medical (MD) | United States | $0.757B | 7.83 |
| Embecta (EMBC) | United States | $0.583B | 3.85 |
| GeneDx Holdings (WGS) | United States | $0.545B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.527B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.525B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.517B | 0.00 |
| Enhabit (EHAB) | United States | $0.511B | 46.27 |
| LifeMD (LFMD) | United States | $0.476B | 0.00 |
| CareDx (CDNA) | United States | $0.475B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.448B | 0.00 |
| MultiPlan (MPLN) | United States | $0.414B | 0.00 |
| Beauty Health (SKIN) | United States | $0.391B | 0.00 |
| DocGo (DCGO) | United States | $0.353B | 56.50 |
| Sera Prognostics (SERA) | United States | $0.338B | 0.00 |
| ModivCare (MODV) | United States | $0.317B | 4.20 |
| Sharecare (SHCR) | United States | $0.263B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.260B | 0.00 |
| Biodesix (BDSX) | United States | $0.143B | 0.00 |
| So-Young (SY) | China | $0.127B | 42.67 |
| Oncology Institute (TOI) | United States | $0.083B | 0.00 |
| Pono Capital Two (PTWO) | United States | $0.071B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.053B | 0.00 |
| NeueHealth (NEUE) | United States | $0.051B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.037B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.035B | 0.00 |
| Singular Genomics Systems (OMIC) | United States | $0.030B | 0.00 |
| Nutex Health (NUTX) | United States | $0.030B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.030B | 0.00 |
| DermTech (DMTK) | United States | $0.021B | 0.00 |
| OncoCyte (OCX) | United States | $0.021B | 0.00 |
| BIMI Holdings (BIMI) | United States | $0.014B | 0.00 |
| Aesthetic Medical Hldngs Group (AIH) | China | $0.013B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.011B | 0.00 | |
| TRxADE HEALTH (MEDS) | United States | $0.008B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.008B | 0.00 |
| XWELL (XWEL) | United States | $0.007B | 0.00 |
| NewGenIvf Group (NIVF) | Singapore | $0.006B | 0.00 |
| OpGen (OPGN) | United States | $0.005B | 0.00 |
| Assure Holdings (IONM) | United States | $0.003B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |